NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 15 of 24
Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study
NCT03013907
On-pump Intraoperative Echocardiography
NCT03094325
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
NCT02968940
Project IMPACT: CHW Intervention
NCT03159533
Music to Reduce Use of Smoking in Patients With Schizophrenia
NCT03190161
C. Difficile and Ursodiol
NCT02748616
Lumbar Manipulation for Hip and Muscle Strength
NCT03101956
Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City
NCT03081507
Data Visualization of Kidney and Prostate Tumors Using Routine Pre-Operative Imaging, 3D Printed, and 3D Virtual Reality Models
NCT03656822
Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS)
NCT03049969
Self-Face Recognition After Face Transplantation
NCT03027141
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NCT02934503
3D MR Versus 3D CT for Glenohumeral Arthritis
NCT03379545
Improving Behavioral Health Care for Children With ADHD
NCT02972086
Prison Connect-STI/HIV Prevention Intervention for Couples Affected by Incarceration
NCT03025191
Home Based Adaptive Arm Training for Children
NCT02751502
Platelet Rich Therapy for Facial Rejuvenation
NCT02730650
Aerobic Exercise and Aphasia Treatment
NCT02999360
A Trial of Cognitive Behavioral Therapy in Familial Dysautonomia
NCT03013777
Evaluation of Patient Reported Outcomes (PRO) After Total Knee Arthroplasty (TKA) Under Spinal Anesthesia
NCT03053453
Driving After Cervical Spine Surgery
NCT02782923
Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children
NCT02991937
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NCT02970981
Acupuncture for Stroke Recovery
NCT02926378
Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
NCT02874092
The Effect of Transjugular Intraheptic Portosystemic Shunt (TIPS) on Gastrointestinal Motility and the Gut Microbiota
NCT03599492
Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome
NCT02758626
Proprioception and Sensorimotor Control in Hereditary Sensory and Autonomic Neuropathy
NCT02876939
Impact of Sleep Workshops in College Students
NCT02665247
fMRI Guided TMS Enhancement of Associative Memory Networks
NCT02749422
C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
NCT02936479
Presurgical Trial of Denosumab in Breast Cancer
NCT02900469
Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure
NCT02935946
Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
NCT02983006
Adapting Project UPLIFT for Hispanic Patients With Epilepsy II
NCT03000725
Home-Based Functional Exercise Program in Patients With Patellar Femoral Syndrome Over a 10-Week Period
NCT03407365
Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery
NCT03325972
Presurgical Motor Mapping With Transcranial Magnetic Stimulation (TMS)
NCT02741193
NSAID vs. Narcotics
NCT02915055
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
NCT02906059
TA-65 Pharmacokinetic Study
NCT02731807
The Effects of Playing Live Music in Music Therapy/Occupational Therapy Co-treatment on Unilateral Spatial Neglect
NCT02919722
Behavioral and Educational Tools to Improve Epilepsy Care
NCT02646631
Vaccination Uptake (VAX) in PD
NCT02874274
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
NCT02875067
The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
NCT03166098
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
NCT02744898
Imaging Biomarkers of Knee Osteoarthritis
NCT02888119
Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome
NCT02854917
Does the Presence of Preoperative Proteinuria Predict Postoperative Acute Kidney Injury in Obese Patients Undergoing Elective Laparoscopic Surgery?
NCT02798042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.